Browsing by Author "Burk, Raymond F."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men
    (Impact Journals, 2017-04-18) Marshall, James R.; Burk, Raymond F.; Ondracek, Rochelle Payne; Hill, Kristina E.; Perloff, Marjorie; Davis, Warren; Pili, Roberto; George, Saby; Bergan, Raymond; Medicine, School of Medicine
    According to the Nutritional Prevention of Cancer (NPC) trial, a selenized yeast supplement containing selenium, 200 mcg/day, decreased the incidence of total cancer, cancers of the prostate, colon and lung, and cancer mortality. The active agent in the selenized yeast supplement was assumed to be selenomethionine (SEMET), although the supplement had not been well speciated. The SELECT study, largely motivated by the NPC trial, enrolling nearly 40 times as many subjects, showed unequivocally that selenium 200 mcg/day, with selenium in the form of SEMET, does not protect selenium-replete men against prostate or other major cancer. The agent tested by SELECT, pure SEMET, could have been different from the selenized yeast tested in NPC. One of the selenium forms suspected of having chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine (MSC). This study, with 29 selenium-replete patients enrolled in a randomized, double-blind trial, compared the multiple-dose toxicity, pharmacokinetics and pharmacodynamics of MSC and SEMET. Patients were on trial for 84 days. No toxicity was observed. Although SEMET supplementation increased blood selenium concentration more than MSC did, neither form had a more than minimal impact on the two major selenoproteins: selenoprotein P(SEPP1) and glutathione peroxidase(GPX).